as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,970.8
Change
-26.3 (-1.32%)
Open
₹2,020.0
Prev. Close
₹1,997.1
Day High
₹2,020.0
Day Low
₹1,950.0
Volume Analysis
Traded
263,825
Delivered
145,320
Delivery %
55.08%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (22.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (3)
- •Strong 3-year EPS growth (34.3%)
- •Strong 3-year revenue growth (15.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,080.54 | ₹2,050.27 | ₹2,010.54 | ₹1,980.27 | ₹1,940.54 | ₹1,910.27 | ₹1,870.54 |
| Fibonacci | ₹2,050.27 | ₹2,023.53 | ₹2,007.01 | ₹1,980.27 | ₹1,953.53 | ₹1,937.01 | ₹1,910.27 |
| Camarilla | ₹1,990.05 | ₹1,983.63 | ₹1,977.22 | ₹1,980.27 | ₹1,964.38 | ₹1,957.97 | ₹1,951.55 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+40.95%
1 Week
-1.93%
1 Month
+1.05%
3 Months
+19.65%
6 Months
+23.08%
1 Year
+43.73%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹567.3
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
16.21%
Net margin 13.58% × asset turnover 0.78x × equity multiplier 1.53x
Company Overview
Sector
Healthcare
Market Cap
₹50,650 Cr
P/E (TTM)
36.9
ROE
15.7%
Book Value
₹318.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Ipca Laboratories Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Valuation (22/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%); promoter holding is falling. Strong 3-year EPS growth (34.3%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- −Stock is trading at 6.28 times its book value
- −Company has a low return on equity of 12.9% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Ipca Q1 FY27 call: 13% domestic growth, 21% consolidated growth, guidance raised to 14-16% and 23% margin.
Ipca Laboratories shared audio link for its 14 August 2026 Q1FY27 earnings and business update call.
Ipca Laboratories’ 76th AGM on 13 Aug 2026 passed all resolutions, including dividend and director reappointments.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 | 2,388 | 2,788 |
| Expenses + | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 | 1,905 | 2,119 |
| Operating Profit | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 | 533 | 484 | 670 |
| OPM % | 19.0% | 18.0% | 16.0% | 16.0% | 19.0% | 19.0% | 21.0% | 19.0% | 18.0% | 21.0% | 22.0% | 20.0% | 24.0% |
| Other Income + | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 | 38 | 48 | 25 |
| Interest | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 | 18 | 20 | 12 |
| Depreciation | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 | 108 | 107 | 111 |
| Profit before tax | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 | 446 | 404 | 572 |
| Tax % | 34.0% | 39.0% | 23.0% | 96.0% | 31.0% | 29.0% | 25.0% | 49.0% | 29.0% | 28.0% | 18.0% | 24.0% | 26.0% |
| Net Profit + | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 |
| EPS in Rs | 6 | 6 | 7 | 2 | 8 | 9 | 10 | 3 | 9 | 11 | 13 | 12 | 16 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,599 | 10,126 |
| Expenses + | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 7,166 | 7,609 | 7,894 |
| Operating Profit | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,990 | 2,232 |
| OPM % | 17.0% | 10.0% | 14.0% | 14.0% | 19.0% | 20.0% | 29.0% | 23.0% | 15.0% | 17.0% | 19.0% | 21.0% | 22.0% |
| Other Income + | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 123 | 17 | -114 | 80 | 81 |
| Interest | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 48 | 141 | 88 | 79 | 69 |
| Depreciation | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 | 357 | 398 | 418 | 429 |
| Profit before tax | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,573 | 1,814 |
| Tax % | 28.0% | 18.0% | 26.0% | 18.0% | 19.0% | 18.0% | 17.0% | 20.0% | 34.0% | 37.0% | 30.0% | 24.0% | — |
| Net Profit + | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 1,184 | 1,375 |
| EPS in Rs | 10 | 4 | 8 | 9 | 18 | 24 | 45 | 35 | 19 | 22 | 29 | 45 | 52 |
| Dividend Payout % | 5.0% | 0.0% | 6.0% | 5.0% | 9.0% | 10.0% | 9.0% | 11.0% | 22.0% | 19.0% | 14.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,602 | 4,676 | 5,467 | 5,817 | 6,307 | 6,923 | 8,038 |
| Borrowings + | 935 | 867 | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | 1,438 | 1,363 | 809 |
| Other Liabilities + | 669 | 765 | 788 | 799 | 961 | 1,130 | 1,099 | 1,338 | 1,300 | 3,326 | 3,432 | 3,477 |
| Total Liabilities | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 8,623 | 11,097 | 11,744 | 12,350 |
| Fixed Assets + | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,418 | 2,751 | 4,554 | 4,267 | 4,627 |
| CWIP | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 | 622 | 773 |
| Investments | 16 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 | 980 | 844 |
| Other Assets + | 1,729 | 1,723 | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,105 | 5,339 | 5,875 | 6,106 |
| Total Assets | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 8,623 | 11,097 | 11,744 | 12,350 |
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | 945 | 1,321 | 1,142 |
| Cash from Investing Activity + | -689 | -218 | -149 | -135 | -165 | -509 | -521 | -851 | -725 | -1,215 | -870 | -247 |
| Cash from Financing Activity + | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | -553 | -283 | -754 |
| Net Cash Flow | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 432 | 588 | -823 | 169 | 142 |
| CFO/OP | 100 | 251 | 74 | 88 | 88 | 80 | 86 | 80 | 110 | 94 | 97 | 78 |
| Free Cash Flow | -207 | 463 | 147 | 206 | 322 | 277 | 731 | 380 | 347 | 543 | 551 | 486 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 8.8% | 8.93% | 8.82% | 9.07% | 8.64% | 8.53% | 8.45% | 8.41% | 8.09% | 7.33% | 7.21% | 7.19% |
| Promoters | 46.29% | 46.29% | 46.3% | 46.3% | 46.3% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% |
| Government | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% |
| FII | 9.86% | 10.27% | 10.51% | 10.85% | 10.83% | 11.06% | 10.75% | 10.67% | 10.42% | 10.62% | 10.63% | 10.72% |
| DII | 34.72% | 34.19% | 34.05% | 33.46% | 33.9% | 35.36% | 35.73% | 35.88% | 36.45% | 36.99% | 37.13% | 37.04% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Ipca Laboratories Ltd (this stock) | 50,650 | 36.9 | 6.28 | 15.7% |
| Anthem Biosciences Ltd | 49,633 | 83.6 | 16.25 | 22.3% |
| Glaxosmithkline Pharma Lt | 47,864 | 45.4 | 21.08 | 45.6% |
| Gland Pharma Limited | 47,846 | 41.8 | 4.61 | 10.7% |
| Ajanta Pharma Limited | 44,229 | 39.0 | 9.78 | 27.1% |
| Global Health Limited | 40,516 | 70.8 | 10.24 | 15.2% |
| Narayana Hrudayalaya Ltd. | 38,040 | 44.1 | 8.38 | 20.5% |
Which Mutual Funds Hold Ipca Laboratories Ltd?
Frequently Asked Questions about Ipca Laboratories Ltd
Ipca Laboratories Ltd (IPCALAB) closed at ₹1,970.8 on NSE on 25 September 2026, down 26.3 (1.32%) from the previous close.
Ipca Laboratories Ltd trades on the NSE (National Stock Exchange of India) under the symbol IPCALAB.
Ipca Laboratories Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 36.9.
Ipca Laboratories Ltd has a dividend yield of 0.3%.
Ipca Laboratories Ltd's 52-week high is ₹2,039.0 and its 52-week low is ₹1,252.0.
Ipca Laboratories Ltd has a market capitalisation of ₹50,650 crore.
Ipca Laboratories Ltd has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Ipca Laboratories Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.